NCT03364348View on ClinicalTrials.gov

4-1BB Agonist Monoclonal Antibody PF-05082566 With Trastuzumab Emtansine or Trastuzumab in Treating Patients With Advanced HER2-Positive Breast Cancer

PHASE1CompletedINTERVENTIONAL
Enrollment

18

Participants

Timeline

Start Date

October 30, 2017

Primary Completion Date

February 15, 2021

Study Completion Date

February 14, 2022

Conditions
HER2 Positive Breast CarcinomaRecurrent Breast CarcinomaStage III Breast CancerStage IIIA Breast CancerStage IIIB Breast CancerStage IIIC Breast CancerStage IV Breast Cancer
Interventions
DRUG

Utomilumab

Given IV

DRUG

Trastuzumab

Given IV

DRUG

Ado-Trastuzumab Emtansine

Given IV

Trial Locations (1)

94304

Stanford University, School of Medicine, Palo Alto

All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

lead

George W. Sledge Jr.

OTHER

NCT03364348 - 4-1BB Agonist Monoclonal Antibody PF-05082566 With Trastuzumab Emtansine or Trastuzumab in Treating Patients With Advanced HER2-Positive Breast Cancer | Biotech Hunter | Biotech Hunter